$4.38
-0.12 (-2.67%)
Open$4.56
Previous Close$4.50
Day High$4.65
Day Low$4.32
52W High$9.38
52W Low$3.91
Volume—
Avg Volume20.2K
Market Cap8.65M
P/E Ratio—
EPS$-17.79
SectorBiotechnology
Analyst Ratings
Buy
11 analysts
Price Target
+502.1% upside
Current
$4.38
$4.38
Target
$26.37
$26.37
$21.16
$26.37 avg
$30.50
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 7.48M | 6.78M | 3.98M |
| Net Income | -32,424,442 | -26,449,739 | 267.7K |
| Profit Margin | -433.7% | -412.1% | 6.7% |
| EBITDA | -33,595,064 | -28,927,137 | 477.9K |
| Free Cash Flow | — | — | 225.1K |
| Rev Growth | +10.3% | +10.3% | +11.2% |
| Debt/Equity | — | — | 0.39 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |